eMedicine Specialties > Hematology > Red Blood Cells and Disorders

Sickle Cell Anemia

Author: Ariel Distenfeld, MD, Clinical Professor, Department of Medicine, New York University School of Medicine
Coauthor(s): Ulrich Woermann, MD, Consulting Staff, Division of Instructional Media, Institute for Medical Education, University of Bern, Switzerland
Contributor Information and Disclosures

Updated: Aug 26, 2009

Introduction

Background

Sickle cell disease (SCD) and its variants are genetic disorders of mutant hemoglobins (Hb). The most common form found in North America is homozygous Hb S disease, first described by Herrick in 1910. Morbidity, frequency of crisis, degree of anemia, and the organ systems involved vary considerably from individual to individual.

Peripheral blood smear with sickled cells at 1000...

Peripheral blood smear with sickled cells at 1000X magnification. Image courtesy of Ulrich Woermann, MD.

Peripheral blood smear with sickled cells at 1000...

Peripheral blood smear with sickled cells at 1000X magnification. Image courtesy of Ulrich Woermann, MD.



Peripheral blood smear with Howell-Jolly body, in...

Peripheral blood smear with Howell-Jolly body, indicating functional asplenism. Image courtesy of Ulrich Woermann, MD.

Peripheral blood smear with Howell-Jolly body, in...

Peripheral blood smear with Howell-Jolly body, indicating functional asplenism. Image courtesy of Ulrich Woermann, MD.

Pathophysiology

Hb S arises from a mutation substituting thymine for adenine in the sixth codon of the beta-chain gene, GAG to GTG. This causes coding of valine instead of glutamate in position 6 of the Hb beta chain. The resulting Hb has the physical properties of forming polymers under deoxy conditions. It also exhibits changes in solubility and molecular stability. These properties are responsible for the profound clinical expressions of the sickling syndromes.


Molecular and cellular changes of hemoglobin S.

Molecular and cellular changes of hemoglobin S.

Molecular and cellular changes of hemoglobin S.

Molecular and cellular changes of hemoglobin S.


Under deoxy conditions, Hb S undergoes marked decrease in solubility, increased viscosity, and polymer formation at concentrations exceeding 30 g/dL. It forms a gel-like substance containing Hb crystals called tactoids. The gel-like form of Hb is in equilibrium with its liquid-soluble form. A number of factors influence this equilibrium, including the following:

  • Oxygen tension
    • Polymer formation occurs only in the deoxy state.
    • If oxygen is present, the liquid state prevails.
  • Concentration of hemoglobin S
    • The normal cellular Hb concentration is 30 g/dL.
    • Gelation of Hb S occurs at concentrations greater than 20.8 g/dL.
  • The presence of other hemoglobins
    • Normal adult hemoglobin (Hb A) and fetal hemoglobin (Hb F) have an inhibitory effect on gelation.
    • These and other Hb interactions affect the severity of clinical syndromes. Hb SS produces a more severe disease than sickle cell Hb C (Hb SC), Hb SD, Hb SO Arab, and Hb with one normal and one sickle allele (Hb SA).

When red blood cells (RBCs) containing homozygous Hb S are exposed to deoxy conditions, the sickling process begins. A slow and gradual polymer formation ensues. Electron microscopy reveals a parallel array of filaments. Repeated and prolonged sickling involves the membrane; the RBC assumes the characteristic sickled shape.

  • After recurrent episodes of sickling, membrane damage occurs and the cells are no longer capable of resuming the biconcave shape upon reoxygenation. Thus, they become irreversibly sickled cells (ISCs). From 5-50% of RBCs permanently remain in the sickled shape.
  • When RBCs sickle, they gain Na+ and lose K+. Membrane permeability to Ca++ increases, possibly due, in part, to impairment in the Ca++ pump that is dependent on adenosine triphosphatase (ATPase). The intracellular Ca++ concentration is 4 times the reference level. The membrane becomes more rigid, possibly due to changes in cytoskeletal protein interactions; however, these changes are not found consistently. Also, whether calcium is responsible for membrane rigidity is not clear.
  • Membrane vesicle formation occurs, and the lipid bilayer is perturbed. The outer leaflet has increased amounts of phosphatidyl ethanolamine and contains phosphatidyl serine. The latter may play a role as a contributor to thrombosis, acting as a catalyst for plasma clotting factors. Membrane rigidity can be reversed in vitro by replacing Hb S with Hb A, suggesting that Hb S interacts with the cell membrane.
  • Sickle cells express very late antigen (VLA)-4 on the surface. VLA-4 interacts with the endothelial cell adhesive molecule, vascular cell adhesive molecule (VCAM)-1. VCAM-1 is upregulated by hypoxia and inhibited by nitric oxide. Hypoxia also decreases nitric oxide production, thereby adding to the adhesion of sickle cells to the vascular endothelium. Nitric oxide is a vasodilator. Free Hb is an avid scavenger of nitric oxide. Because of the continuing active hemolysis, there is free Hb in the plasma, and it scavenges nitric oxide. This makes it less available and contributes to vasoconstriction.
  • Sickle RBCs adhere to endothelium because of increased stickiness. The endothelium participates in this process as do neutrophils, which also express increased levels of adhesive molecules.
  • Deformable sickle cells express CD18 and adhere abnormally to endothelium up to 10 times more than normal cells, while ISCs do not. As paradoxical as it might seem, individuals who produce large numbers of ISCs have fewer vasoocclusive crises than those with more deformable RBCs.
  • Sickle cells also adhere to macrophages. This property may contribute to erythrophagocytosis and the hemolytic process. The microvascular perfusion at the level of the prearterioles is influenced by RBCs containing Hb S polymers. This occurs at arterial oxygen saturation, before any morphologic change is apparent.
  • Hemolysis is a constant finding in sickle cell syndromes. Approximately one third of RBCs undergo intravascular hemolysis, possibly due to loss of membrane filaments during oxygenation and deoxygenation. The remainder hemolyze by erythrophagocytosis by macrophages. This process can be partially modified by Fc (crystallizable fragment) blockade, suggesting that the process can be mediated by immune mechanisms.
  • Sickle RBCs have increased immunoglobulin G (IgG) on the cell surface. Vasoocclusive crisis is often triggered by infection. Levels of fibrinogen and fibronectin and the D-dimer are elevated in these patients. Plasma clotting factors likely participate in the microthrombi in the prearterioles.
  • These physiological changes result in a disease with the following cardinal signs: (1) hemolytic anemia, (2) painful vasoocclusive crisis, and (3) multiple organ damage with microinfarcts, including heart, skeleton, spleen, and central nervous system.

Frequency

United States

The sickle gene is present in approximately 8% of black Americans. The expected incidence of sickle cell anemia in the United States is 1 in 625 persons at birth. The actual prevalence is less because of early mortality. More than 2 million people in the United States, nearly all of them of African American ancestry, carry the sickle gene. More than 30,000 patients have homozygous Hb S disease.

International

In several sections of Africa, the prevalence of sickle cell trait (heterozygote) is as high as 30%.

Mortality/Morbidity

  • SCD diagnosis is suggested with the typical clinical picture of chronic hemolytic anemia and vasoocclusive crisis. It is confirmed when the presence of homozygous Hb S is demonstrated by electrophoresis. This test documents Hb SS, Hb SC, or Hb S-beta+ thalassemia, as common examples. Patients with Hb SA are heterozygous carriers and essentially are asymptomatic. Morbidity is highly variable in patients with SCD, partly depending on the level of Hb F. Nearly all individuals with the condition are affected to some degree and experience multiple organ system involvement. Vasoocclusive crisis and chronic pain are associated with considerable economic loss and disability.
  • Mortality is high, especially in the early childhood years. Since the introduction of widespread penicillin prophylaxis and pneumococcal vaccination, a marked reduction has been observed in childhood deaths. The leading cause of death is acute chest syndrome. Based on data from the cooperative study of the SCD group in 1995, the life expectancy is 42 years for males and 48 years for females. Median survival is approaching 50 years, which is considerably less than life expectancy for African Americans who do not have SCD.
  • In Africa, available mortality data are sporadic and incomplete. Many children are not diagnosed, especially in rural areas, and death is often attributed to malaria or other comorbid conditions.

Race

SCD is present mostly in blacks. It also is found, with much less frequency, in eastern Mediterranean and Middle East populations.

Sex

The male-to-female ratio is 1:1.

Age

SCD is a lifelong condition. It first manifests in the second half of the first year of life and persists for the entire lifespan.

Clinical

History

The presenting symptoms of SCD involve pain and anemia.

  • SCD usually manifests early in childhood.
    • For the first 6 months of life, infants are protected largely by elevated levels of Hb F; soon thereafter, the condition becomes evident.
    • The following 3 prognostic factors have been identified as predictors of an adverse outcome: (1) dactylitis in infants younger than 1 year, (2) Hb level of less than 7 g/dL, and (3) leukocytosis in the absence of infection.
  • The most common clinical picture during adult life is vasoocclusive crisis.
    • The crisis begins suddenly, sometimes as a consequence of infection or temperature change, such as an air-conditioned environment during a hot summer day. However, often, no precipitating cause can be identified.
    • Severe deep pain is present in the extremities, involving long bones. The abdomen is affected with severe pain resembling acute abdomen. The face also may be involved. Pain may be accompanied by fever, malaise, and leukocytosis. The person in crisis is in extreme discomfort.
    • The crisis may last several hours to several days and terminate as abruptly as it began.
  • Approximately half the individuals with homozygous Hb S disease experience vasoocclusive crisis.
    • The frequency of crisis is extremely variable. Some have as many as 6 or more episodes annually, whereas others may have episodes only at great intervals or none at all.
    • Each individual typically has a consistent pattern for crisis frequency.
  • Many individuals with Hb S disease experience chronic low-level pain, mainly in bones and joints. Intermittent vasoocclusive crisis may be superimposed, or chronic low-level pain may be the only expression of the disease.
  • Anemia is universally present.
    • It is chronic and hemolytic in nature and usually very well tolerated.
    • While patients with an Hb level of 6-7 g/dL who are able to participate in the activities of daily life in a normal fashion are not uncommon, their tolerance for exercise and exertion tends to be very limited.
    • Anemia may be complicated with megaloblastic changes secondary to folate deficiency. These result from increased RBC turnover and folate utilization. Periodic bouts of hyperhemolysis may occur.
    • A serious complication is the aplastic crisis.
      • This is caused by infection with the Parvovirus B-19 (B19V). The virus infects RBC progenitors in bone marrow, resulting in cessation of erythropoiesis.
      • Coupled with greatly shortened RBC lifespan, usually 10-20 days, a very rapid drop in Hb occurs.
      • The condition is self-limited, with bone marrow recovery occurring in 7-10 days, followed by brisk reticulocytosis.
  • During childhood and adolescence, the disease is associated with growth retardation, delayed sexual maturation, and being underweight. Over a 2-year period, Rhodes et al assessed preadolescent children with homozygous sickle cell anemia to determine a correlation between the causes of impaired growth and maturation with metabolic and hematologic factors during puberty in these children.84 Height, weight, body mass index, and body composition changes were longitudinally and compared between the groups and with Z scores based on US growth charts.The investigators found children with sickle cell anemia progressed more slowly through puberty than healthy control children. Affected pubertal males were shorter and had significantly slower height growth than their unaffected counterparts, with a decline in height over time; however, the annual weight increases didn't differ between the 2 groups of males.84 In addition, the mean fat free mass increments in affected males and females were significantly less than those of the control children. Overall, Rhodes et al demonstrated children with sickle cell anemia have growth delays during puberty and the decreased growth velocity is independently associated with decreased Hb concentration and increased total energy expenditure.84 Several other processes also occur at this time.
    • The spleen enlarges in the latter part of the first year of life.
      • Occasionally, it undergoes a sudden very painful enlargement due to pooling of large numbers of sickled cells. This phenomenon is known as splenic sequestration crisis.
      • The spleen undergoes repeated infarction, aided by low pH and low oxygen tension in the sinusoids and splenic cords.
      • Even while enlarged, its function is impaired, as evidenced by its failure to take up particulate matter such as technetium during nuclear scanning.
      • Over time, the spleen becomes fibrotic and shrinks. This is, in fact, an autosplenectomy.
      • The nonfunctional spleen is a major contributor to the immune deficiency that exists in these individuals. Failure of opsonization and an inability to deal with infective encapsulated microorganisms, particularly Streptococcus pneumoniae, ensue.
    • Pneumococcal infections are common in childhood.
      • During adult life, infections with gram-negative organisms, especially Salmonella, predominate.
      • Of special concern is the frequent occurrence of Salmonella osteomyelitis in areas of bone weakened by infarction.
  • Another problem occurring in infancy is hand-foot syndrome.
    • This is a dactylitis presenting as painful swelling of the dorsum of the hand and foot.
    • Cortical thinning and destruction of the metacarpal and metatarsal bones appear on radiographs 3-5 weeks after the swelling begins.
    • Leukocytosis or erythema does not accompany the swelling.
  • The acute chest syndrome consists of chest pain, fever, tachypnea, leukocytosis, and pulmonary infiltrates.
    • This is a medical emergency and must be treated immediately.
    • It probably begins with infarction of ribs, leading to chest splinting and atelectasis.
    • Fat embolism, resulting from bone marrow infarction, plays an important etiological role in the pathogenesis of this syndrome.
    • If not attended to promptly, it may lead to acute respiratory distress syndrome (ARDS).
  • Central nervous system involvement is one of the most devastating aspects of SCD.
    • It is most prevalent in childhood and adolescence.
    • The most severe manifestation is stroke, resulting in varying degrees of neurological deficit. The stroke is mostly thrombotic, but it may also be hemorrhagic.
    • Vigorous diagnostic and therapeutic efforts may have a beneficial impact on the outcome of this condition. All children with SCD should be screened with transcranial Doppler. Those in whom increased velocity is found should be considered for chronic transfusion therapy, maintaining the level of Hb S at 30% or less. The specific cut off point depends on the method used and is lower for duplex Doppler.
  • The heart is involved due to chronic anemia and microinfarcts.
    • Hemolysis and blood transfusion lead to hemosiderin deposition in the myocardium.
    • Both ventricles and the left atrium are all dilated.
    • Usually, a systolic murmur is present, with wide radiation over the precordium.
  • Chronic hemolysis with hyperbilirubinemia is associated with the formation of bile stones. Cholelithiasis may be asymptomatic or result in acute cholecystitis, requiring surgical intervention. In addition, a hepatopathy may be present.
  • Repeated infarction of joints, bones, and growth plates leads to aseptic necrosis, especially in weightbearing areas such as the femur. This complication is associated with chronic pain and disability and may require changes in employment and lifestyle.
  • Blood in the pulmonary circulation is deoxygenated, resulting in a high degree of polymer formation.
    • The lungs develop areas of microinfarction. The resulting areas that lack oxygenation aggravate the sickling process.
    • Pulmonary hypertension may develop. This may be due in part to the depletion of nitric oxide. Various studies have found that more than 40% of adults with SCD have pulmonary hypertension that worsens with age.
  • The kidneys lose concentrating capacity.
    • Isosthenuria results in a large loss of water, further contributing to dehydration in these patients. Renal failure may ensue, usually preceded by proteinuria.
    • Nephrotic syndrome is uncommon but may occur.
  • Paraorbital facial infarction may result in ptosis.
    • Retinal vascular changes also occur.
    • A proliferative retinitis is common in Hb SC disease and may lead to loss of vision.
  • Leg ulcers are a chronic painful problem. They result from minor injury to the area around the malleoli. Because of relatively poor circulation, compounded by sickling and microinfarcts, healing is delayed and infection is established.
  • Priapism is a serious complication and tends to occur repeatedly. When it is prolonged, it may lead to impotence.
  • Pregnancy represents a special area of concern. The high rate of fetal loss is due to spontaneous abortion. Placenta previa and abruption are common due to hypoxia and placental infarction. At birth, the infant often is premature or has low birth weight.

Physical

  • Physical findings are not specific.
    • Scleral icterus is present, and, upon ophthalmoscopic examination of the conjunctiva with the +40 lens, abnormal or corkscrew-shaped blood vessels may be seen.
    • The mucous membranes are pale.
    • A systolic murmur may be heard over the entire precordium.
    • In childhood, splenomegaly is present, although this is not present in adults due to autosplenectomy. In adulthood, leg ulcers may be found over the malleoli.

Causes

  • SCD originated in West Africa, where it has the highest prevalence.
    • It also is present to a lesser extent in India and the Mediterranean region.
    • DNA polymorphism of the beta S gene suggests that it arose from 5 separate mutations, 4 in Africa and 1 in India and the Middle East.
      • The most common of these is an allele found in Benin in West Africa.
      • The other haplotypes are found in Senegal and Bantu, Africa, as well as in India and the Middle East.
  • The Hb S gene, when present in homozygous form, is an undesirable mutation, so a selective advantage in the heterozygous form must account for its high prevalence and persistence.
    • Malaria is possibly the selecting agent because a concordance exists between the prevalence of malaria and Hb S. Sickling might protect a person from malaria by either of the following:
      • Accelerating sickling so that parasitized cells are removed
      • Making it more difficult for the parasite to metabolize or to enter the sickled cell
    • While children with sickle cell trait Hb SA seem to have a milder form of falciparum malaria, those with homozygous Hb S have a severe form that is associated with very high mortality rate.

More on Sickle Cell Anemia

Overview: Sickle Cell Anemia
Differential Diagnoses & Workup: Sickle Cell Anemia
Treatment & Medication: Sickle Cell Anemia
Follow-up: Sickle Cell Anemia
Multimedia: Sickle Cell Anemia
References
Further Reading

References

  1. Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials. Feb 1998;19(1):110-29. [Medline].

  2. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. Jul 2 1998;339(1):5-11. [Medline].

  3. Alikhan M, Carter G, Mehta P. Topical GM-CSF hastens healing of leg ulcers in sickle cell disease. Am J Hematol. Jun 2004;76(2):192. [Medline].

  4. Aslan M, Freeman B. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease--mechanisms and consequences. Cell Mol Biol (Noisy-le-grand). Feb 2004;50(1):95-105. [Medline].

  5. Ataga K, Sood N, De Gent G, et al. Pulmonary hypertension in sickle cell disease. Am J Med. Nov 1 2004;117(9):665-9. [Medline].

  6. Ballas SK. Complications of sickle cell anemia in adults: guidelines for effective management. Cleve Clin J Med. Jan 1999;66(1):48-58. [Medline].

  7. Ballas SK. Management of sickle pain. Curr Opin Hematol. Mar 1997;4(2):104-11. [Medline].

  8. Beyer JE, Platt AF, Kinney TR, Treadwell M. Practice guidelines for the assessment of children with sickle cell pain. J Soc Pediatr Nurs. Apr-Jun 1999;4(2):61-73. [Medline].

  9. Bookchin RM, Lew VL. Pathophysiology of sickle cell anemia. Hematol Oncol Clin North Am. Dec 1996;10(6):1241-53. [Medline].

  10. Bunn HF. Induction of fetal hemoglobin in sickle cell disease. Blood. Mar 15 1999;93(6):1787-9. [Medline].

  11. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. Sep 11 1997;337(11):762-9. [Medline].

  12. Burnett MW, Bass JW, Cook BA. Etiology of osteomyelitis complicating sickle cell disease. Pediatrics. Feb 1998;101(2):296-7. [Medline].

  13. Castro O. Management of sickle cell disease: recent advances and controversies. Br J Haematol. Oct 1999;107(1):2-11. [Medline].

  14. Charache S. Eye disease in sickling disorders. Hematol Oncol Clin North Am. Dec 1996;10(6):1357-62. [Medline].

  15. Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol. Jul 1997;34(3 Suppl 3):15-21. [Medline].

  16. Charache S. Treatment of sickling disorders. Curr Opin Hematol. Mar 1996;3(2):139-44. [Medline].

  17. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. May 18 1995;332(20):1317-22. [Medline].

  18. Chung C, Cackovic M, Kerstein MD. Leg ulcers in patients with sickle cell disease. Adv Wound Care. Sep-Oct 1996;9(5):46-50. [Medline].

  19. Crowley JJ, Sarnaik S. Imaging of sickle cell disease. Pediatr Radiol. Sep 1999;29(9):646-61. [Medline].

  20. Curran EL, Fleming JC, Rice K, Wang WC. Orbital compression syndrome in sickle cell disease. Ophthalmology. Oct 1997;104(10):1610-5. [Medline].

  21. Danzer BI, Birnbach DJ, Thys DM. Anesthesia for the parturient with sickle cell disease. J Clin Anesth. Nov 1996;8(7):598-602. [Medline].

  22. Davies SC. Blood transfusion in sickle cell disease. Curr Opin Hematol. Nov 1996;3(6):485-91. [Medline].

  23. Duncan GW. Ischemic stroke in sickle cell disease: a review. Tenn Med. Dec 1997;90(12):498-9. [Medline].

  24. Eckman JR. Leg ulcers in sickle cell disease. Hematol Oncol Clin North Am. Dec 1996;10(6):1333-44. [Medline].

  25. Elander J, Midence K. A review of evidence about factors affecting quality of pain management in sickle cell disease. Clin J Pain. Sep 1996;12(3):180-93. [Medline].

  26. Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol. Jul 2004;76(3):245-51. [Medline].

  27. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol. Jan 1999;26(1):74-84. [Medline].

  28. Firth PG, Head CA. Sickle cell disease and anesthesia. Anesthesiology. Sep 2004;101(3):766-85. [Medline].

  29. Forbes K, Forbes B, Lee A. Re: Sickle cell-related pain: perceptions of medical practitioners. [letter; comment]. J Pain Symptom Manage. Jun 1998;15(6):333-4. [Medline].

  30. Gebreyohanns M, Adams RJ. Sickle cell disease: primary stroke prevention. CNS Spectr. Jun 2004;9(6):445-9. [Medline].

  31. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. Feb 26 2004;350(9):886-95. [Medline].

  32. Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet. May 1998;34(5):347-58. [Medline].

  33. Haberkern CM, Neumayr LD, Orringer EP, et al. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group. Blood. Mar 1 1997;89(5):1533-42. [Medline].

  34. Hackney AC, Hezier W, Gulledge TP, et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clin Sci (Lond). May 1997;92(5):481-6. [Medline].

  35. Hardwick WE Jr, Givens TG, Monroe KW, et al. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care. Jun 1999;15(3):179-82. [Medline].

  36. Harmatz P, Heyman MB, Cunningham J, et al. Effects of red blood cell transfusion on resting energy expenditure in adolescents with sickle cell anemia. J Pediatr Gastroenterol Nutr. Aug 1999;29(2):127-31. [Medline].

  37. Hillery CA. Potential therapeutic approaches for the treatment of vaso-occlusion in sickle cell disease. Curr Opin Hematol. Mar 1998;5(2):151-5. [Medline].

  38. Hilliard LM, Williams BF, Lounsbury AE, Howard TH. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol. Sep 1998;59(1):28-35. [Medline].

  39. Howard LW, Kennedy LD. Hydroxyurea in the treatment of sickle-cell anemia. Ann Pharmacother. Nov 1997;31(11):1393-6. [Medline].

  40. Howlett DC, Hatrick AG, Jarosz JM, et al. The role of CT and MR in imaging the complications of sickle cell disease. Clin Radiol. Nov 1997;52(11):821-9. [Medline].

  41. Jacobson SJ, Kopecky EA, Joshi P, Babul N. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet. Nov 8 1997;350(9088):1358-61. [Medline].

  42. Kaul DK, Tsai HM, Liu XD, et al. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood. Jan 15 2000;95(2):368-74. [Medline].

  43. Kerle KK, Nishimura KD. Exertional collapse and sudden death associated with sickle cell trait. Mil Med. Dec 1996;161(12):766-7. [Medline].

  44. Kerstein MD. The non-healing leg ulcer: peripheral vascular disease, chronic venous insufficiency, and ischemic vasculitis. Ostomy Wound Manage. Nov-Dec 1996;42(10A Suppl):19S-35S. [Medline].

  45. Kinney TR, Helms RW, O''Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. Sep 1 1999;94(5):1550-4. [Medline].

  46. Lawrenz DR. Sickle cell disease: a review and update of current therapy. J Oral Maxillofac Surg. Feb 1999;57(2):171-8. [Medline].

  47. Lawton AW. Sickle cell and the eye. ABNF J. May-Jun 1996;7(3):78-80. [Medline].

  48. Lum AF, Wun T, Staunton D, Simon S. Inflammatory potential of neutrophils detected in sickle cell disease. Am J Hematol. Jun 2004;76(2):126-33. [Medline].

  49. Martin JJ, Moore GP. Pearls, pitfalls, and updates for pain management. Emerg Med Clin North Am. May 1997;15(2):399-415. [Medline].

  50. McCarville MB, Li C, Xiong X, Wang W. Comparison of transcranial Doppler sonography with and without imaging in the evaluation of children with sickle cell anemia. AJR Am J Roentgenol. Oct 2004;183(4):1117-22. [Medline].

  51. Meshikhes AW, al-Faraj AA. Sickle cell disease and the general surgeon. J R Coll Surg Edinb. Apr 1998;43(2):73-9. [Medline].

  52. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. Jan 13 2000;342(2):83-9. [Medline].

  53. Miniero R, Rocha V, Saracco P, et al. Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord. Bone Marrow Transplant. Jul 1998;22 Suppl 1:S78-9. [Medline].

  54. Montgomery KS. Caring for the pregnant woman with sickle cell disease. MCN Am J Matern Child Nurs. Sep-Oct 1996;21(5):224-8. [Medline].

  55. Murray MJ, Evans P. Sudden exertional death in a soldier with sickle cell trait. Mil Med. May 1996;161(5):303-5. [Medline].

  56. Ohene-Frempong K, Smith-Whitley K. Use of hydroxyurea in children with sickle cell disease: what comes next?. Semin Hematol. Jul 1997;34(3 Suppl 3):30-41. [Medline].

  57. Olney RS. Preventing morbidity and mortality from sickle cell disease. A public health perspective. Am J Prev Med. Feb 1999;16(2):116-21. [Medline].

  58. Overturf GD. Infections and immunizations of children with sickle cell disease. Adv Pediatr Infect Dis. 1999;14:191-218. [Medline].

  59. Powars DR, Johnson CS. Priapism. Hematol Oncol Clin North Am. Dec 1996;10(6):1363-72. [Medline].

  60. Quinn CT, Buchanan GR. The acute chest syndrome of sickle cell disease. J Pediatr. Oct 1999;135(4):416-22. [Medline].

  61. Reed W, Vichinsky EP. New considerations in the treatment of sickle cell disease. Annu Rev Med. 1998;49:461-74. [Medline].

  62. Reed WF, Vichinsky EP. Transfusion practice for patients with sickle cell disease. Curr Opin Hematol. Nov 1999;6(6):432-6. [Medline].

  63. Rodgers GP. Overview of pathophysiology and rationale for treatment of sickle cell anemia. Semin Hematol. Jul 1997;34(3 Suppl 3):2-7. [Medline].

  64. Saborio P, Scheinman JI. Sickle cell nephropathy. J Am Soc Nephrol. Jan 1999;10(1):187-92. [Medline].

  65. Schnog JJ, Lard LR, Rojer RA, et al. New concepts in assessing sickle cell disease severity. Am J Hematol. May 1998;58(1):61-6. [Medline].

  66. Serjeant GR. The role of preventive medicine in sickle cell disease. The Watson Smith lecture. J R Coll Physicians Lond. Jan-Feb 1996;30(1):37-41. [Medline].

  67. Shaiova L, Wallenstein D. Outpatient management of sickle cell pain with chronic opioid pharmacotherapy. J Natl Med Assoc. Jul 2004;96(7):984-6. [Medline].

  68. Simon TL, Alverson DC, AuBuchon J, et al. Practice parameter for the use of red blood cell transfusions: developed by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists. Arch Pathol Lab Med. Feb 1998;122(2):130-8. [Medline].

  69. Smith JA. Bone disorders in sickle cell disease. Hematol Oncol Clin North Am. Dec 1996;10(6):1345-56. [Medline].

  70. Steinberg MH. Management of sickle cell disease. N Engl J Med. Apr 1 1999;340(13):1021-30. [Medline].

  71. Steinberg MH. Review: sickle cell disease: present and future treatment. Am J Med Sci. Oct 1996;312(4):166-74. [Medline].

  72. Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. Feb 1 1997;89(3):1078-88. [Medline].

  73. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. Oct 9 2004;364(9442):1343-60. [Medline].

  74. Tachakra SS, Davies SC. Management of sickle cell crisis. British Association for Accident and Emergency Medicine guidelines. J Accid Emerg Med. Sep 1998;15(5):356-7. [Medline].

  75. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell anemia. Curr Opin Hematol. Mar 1996;3(2):163-6. [Medline].

  76. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. Jul 1998;22(1):1-6. [Medline].

  77. Vichinsky E, Styles L. Pulmonary complications. Hematol Oncol Clin North Am. Dec 1996;10(6):1275-87. [Medline].

  78. Walters MC, Patience M, Leisenring W, et al. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. Biol Blood Marrow Transplant. Dec 1997;3(6):310-5. [Medline].

  79. Wick TM, Eckman JR. Molecular basis of sickle cell-endothelial cell interactions. Curr Opin Hematol. Mar 1996;3(2):118-24. [Medline].

  80. Williams R, Olivi S, Li CS, et al. Oral glutamine supplementation decreases resting energy expenditure in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. Oct 2004;26(10):619-25. [Medline].

  81. Wintrobe MM. Lee GL, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Clinical Hematology. Vol 1. 10th ed. Baltimore, Md: Williams & Wilkins;1999: 1329-98.

  82. Zen Q, Batchvarova M, Twyman CA, et al. B-CAM/LU expression and the role of B-CAM/LU activation in binding of low- and high-density red cells to laminin in sickle cell disease. Am J Hematol. Feb 2004;75(2):63-72. [Medline].

  83. Roberts L, O'Driscoll S, Dick MC, et al. Stroke prevention in the young child with sickle cell anaemia. Ann Hematol. Oct 2009;88(10):943-6. [Medline].

  84. Rhodes M, Akohoue SA, Shankar SM, et al. Growth patterns in children with sickle cell anemia during puberty. Pediatr Blood Cancer. Oct 2009;53(4):635-41. [Medline].

  85. Al-Subaie AM, Mahdi N, Al-Absi IK, et al. Human platelet alloantigens (HPA) 1, HPA2, HPA3, HPA4, and HPA5 polymorphisms in sickle cell anemia patients with vaso-occlusive crisis. Eur J Haematol. Aug 21 2009;[Medline].

Further Reading

Related eMedicine Topics

Clinical Trials
National Guideline Clearinghouse

Keywords

sickle cell disease, hemoglobin SS disease, sickle cell trait, homozygous hemoglobin S disease, SCD, mutant hemoglobins, Hb S, Hb SS, Hb A, Hb SA, anemia, red blood cells, RBC, sickle shaped, vasoocclusive crisis, sickle cell crisis, hemoglobin sc disease, hemoglobin c disease, thalassemia, congenital hemolytic anemia, hemoglobinopathies

Contributor Information and Disclosures

Author

Ariel Distenfeld, MD, Clinical Professor, Department of Medicine, New York University School of Medicine
Ariel Distenfeld, MD is a member of the following medical societies: American Academy of Hospice and Palliative Medicine, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, International Society of Blood Transfusion, International Society of Hematology, Medical Society of the State of New York, and New York Academy of Sciences
Disclosure: Nothing to disclose.

Coauthor(s)

Ulrich Woermann, MD, Consulting Staff, Division of Instructional Media, Institute for Medical Education, University of Bern, Switzerland
Disclosure: Nothing to disclose.

Medical Editor

Wadie F Bahou, MD, Chief, Division of Hematology, Hematology/Oncology Fellowship Director, Professor, Department of Internal Medicine, State University of New York at Stony Brook
Wadie F Bahou, MD is a member of the following medical societies: American Society of Hematology
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Marcel E Conrad, MD, (Retired) Distinguished Professor of Medicine, University of South Alabama
Marcel E Conrad, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Blood Banks, American Chemical Society, American College of Physicians, American Physiological Society, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Association of Military Surgeons of the US, International Society of Hematology, Society for Experimental Biology and Medicine, and Southwest Oncology Group
Disclosure: No financial interests None None

CME Editor

Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University
Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, and New York Academy of Sciences
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.